# White House Schedules Meeting on FDA’s New CBD Compliance Enforcement Policy > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-industry-news-fda-compliance-enforcement-policy/ > **Published:** 2026-03-26T15:03:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:18:21-04:00 > **Clinical Summary:** Stay updated on CBD industry news with FDA's new compliance enforcement policy impacting product quality and patient access. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic CbdFda PolicyProduct QualityRegulatory[Patient Access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) Why This Matters FDA enforcement policy directly affects [product availability](https://cedclinic.com/cannabis-industry-consolidation-trends-patient-access/), quality standards, and legal clarity for clinicians recommending [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). Changes in regulatory oversight could impact [patient access](https://cedclinic.com/iowa-medical-cannabis-dispensaries-expansion/) to consistent, laboratory-tested CBD formulations that clinicians rely on for therapeutic applications. Clinical Summary The White House has scheduled a meeting regarding FDA’s new compliance enforcement policy for [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/). This regulatory development occurs amid ongoing uncertainty about CBD’s legal status for dietary supplements and food products, despite widespread consumer use and growing clinical interest. The FDA has historically maintained that CBD cannot be legally marketed in foods or dietary supplements, though enforcement has been inconsistent. Any policy shift could affect product availability, manufacturing standards, and [quality control](https://cedclinic.com/alabama-medical-cannabis-commission-audit-violations/) measures that impact clinical outcomes. Dr. Caplan’s Take “Regulatory clarity has been the missing piece for both clinicians and patients navigating CBD therapeutics. Whatever emerges from this policy discussion, I’ll be watching for how it affects access to properly tested, consistent CBD products that we can actually recommend with confidence.” Clinical Perspective 🧠 Clinicians should monitor how policy changes affect their local CBD product landscape and quality standards. Continue recommending only third-party tested products from reputable manufacturers regardless of regulatory shifts. Patients using CBD should be prepared for potential market changes that could affect their current products’ availability or formulation. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20White%20House%20Schedules%20Meeting%20for%20FDA%27s%20New%20CBD%20Compliance%20Enforcement%20Policy%20%40drcaplan&url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20White%20House%20Schedules%20Meeting%20for%20FDA%27s%20New%20CBD%20Compliance%20Enforcement%20Policy%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy](https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy) Table of Contents - [FAQ](#FAQ)[What is the current FDA policy on CBD products?](#What_is_the_current_FDA_policy_on_CBD_products) - [Why is product quality a concern with CBD products?](#Why_is_product_quality_a_concern_with_CBD_products) - [What regulatory challenges does CBD face?](#What_regulatory_challenges_does_CBD_face) - [How does this regulatory uncertainty affect patients and healthcare providers?](#How_does_this_regulatory_uncertainty_affect_patients_and_healthcare_providers) - [What should consumers know about CBD product safety?](#What_should_consumers_know_about_CBD_product_safety) - [Related](#Related) ## FAQ #### What is the current FDA policy on CBD products? The FDA has not approved CBD for use in dietary supplements or food products, except for one prescription drug (Epidiolex). The agency continues to evaluate the regulatory framework for CBD products and has expressed concerns about safety and quality control. #### Why is product quality a concern with CBD products? Many CBD products on the market lack proper quality control and may contain inaccurate labeling of CBD content. Without FDA oversight, consumers may encounter products with contaminants, inconsistent dosing, or misleading claims about their effects. #### What regulatory challenges does CBD face? CBD exists in a complex regulatory gray area between food, supplement, and drug categories. The FDA is working to establish clear guidelines while balancing public safety concerns with growing consumer demand and industry pressure. #### How does this regulatory uncertainty affect patients and healthcare providers? Healthcare providers face challenges in recommending CBD products due to lack of standardization and regulatory clarity. Patients may struggle to find reliable, consistent products and accurate dosing information for their medical needs. #### What should consumers know about CBD product safety? Consumers should research CBD products carefully, look for third-party testing results, and consult healthcare providers before use. Until clearer regulations are established, buyers should be cautious about product claims and quality variations in the marketplace. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “White House Schedules Meeting for FDA’s New CBD Compliance Enforcement Policy”, “url”: “https://www.cannabisbusinesstimes.com/business-issues-benchmarks/cbd-industry/news/15820674/white-house-schedules-meeting-for-fdas-new-cbd-compliance-enforcement-policy”, “datePublished”: “2026-03-26T15:52:15Z”, “about”: “white house schedules meeting fda s”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [White House Schedules Meeting On Cannabis Products Enforcement Policy For Next Week](https://cedclinic.com/cannabis-products-enforcement-policy-meeting-scheduled/) Explore details about the upcoming White House meeting focused on cannabis product enforcement policies and its implications. [Read More](https://cedclinic.com/cannabis-products-enforcement-policy-meeting-scheduled/) [Review Finds Just 31% of Consumer CBD Products Meet Label-Accuracy Standard](https://cedclinic.com/review-finds-just-31-of-consumer-cbd-products-meet-label-accuracy-standard/) Learn about the challenges in CBD product quality and label accuracy affecting consumer trust and safety. [Learn More](https://cedclinic.com/review-finds-just-31-of-consumer-cbd-products-meet-label-accuracy-standard/) [CBD Gummies in NC: What North Carolina Residents Need to Know in 2026](https://cedclinic.com/cbd-gummies-male-enhancement-marketing-concerns/) Get informed on the latest regulations and market updates for CBD gummies in North Carolina for 2026. [Discover More](https://cedclinic.com/cbd-gummies-male-enhancement-marketing-concerns/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).